Oblique Therapeutics
  • Home Page
  • About us
    • Overview
    • Organization
  • Technology
    • AbiprotTM-antibody platform
    • Abiprot SelectTM
  • Portfolio
    • Overview
    • OT-1096 in TNBC
    • aTRPV1 & aTRPA1 in pain
    • aKRAS in colorectal cancer
    • Collaborations in type 2 diabetes
  • Corporate Governance
    • General annual meetings
    • Board of Directors and Management
    • Nomination Committee
  • Investors Relations
    • Financial Reports
  • News
    • Press Releases
    • Publications, conferences & press
  • Contact
Oblique Therapeutics > News > News > 24th Sept 2020 – Oblique Therapeutics is delighted to be invited to speak at “Biopharma Conclave 2020”
  • Home Page
  • About us
    • Overview
    • Organization
  • Technology
    • AbiprotTM-antibody platform
    • Abiprot SelectTM
  • Portfolio
    • Overview
    • OT-1096 in TNBC
    • aTRPV1 & aTRPA1 in pain
    • aKRAS in colorectal cancer
    • Collaborations in type 2 diabetes
  • Corporate Governance
    • General annual meetings
    • Board of Directors and Management
    • Nomination Committee
  • Investors Relations
    • Financial Reports
  • News
    • Press Releases
    • Publications, conferences & press
  • Contact
Archive
  • March 2021
  • November 2020
  • October 2020
  • September 2020
  • June 2020
  • November 2019
  • October 2019
  • July 2019
  • March 2019
  • January 2019
  • November 2018
  • October 2018
Categories
  • Company updates
  • News
21 Sep 2020

24th Sept 2020 – Oblique Therapeutics is delighted to be invited to speak at “Biopharma Conclave 2020”

 

Abstract Sreesh BioPharma Conclave congress 2020

Biologics and Cell & Gene Therapy Agenda 2020

Oblique Therapeutics

Copyright © 2021 Oblique Therapeutics AB.

Contact

Oblique Therapeutics AB
info@obliquet.com

Gothenburg
Arvid Wallgrens Backe 20
413 46 Göteborg
Sweden

Stockholm
Döbelnsgatan 64
113 52 Stockholm
Sweden

Menu
  • Home Page
  • About us
    • Overview
    • Organization
  • Technology
    • AbiprotTM-antibody platform
    • Abiprot SelectTM
  • Portfolio
    • Overview
    • OT-1096 in TNBC
    • aTRPV1 & aTRPA1 in pain
    • aKRAS in colorectal cancer
    • Collaborations in type 2 diabetes
  • Corporate Governance
    • General annual meetings
    • Board of Directors and Management
    • Nomination Committee
  • Investors Relations
    • Financial Reports
  • News
    • Press Releases
    • Publications, conferences & press
  • Contact
About

Oblique Therapeutics is a privately held Swedish biotech developing innovative new medicines for severe diseases with a large unmet medical need focusing on pain, and advanced cancer.  The company uses AbiprotTM, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. 

Till toppen